BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 22682017)

  • 1. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma.
    Scotlandi K; Manara MC; Hattinger CM; Benini S; Perdichizzi S; Pasello M; Bacci G; Zanella L; Bertoni F; Picci P; Serra M
    Eur J Cancer; 2005 Jun; 41(9):1349-61. PubMed ID: 15913990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
    Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
    Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
    Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
    Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
    Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
    Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study.
    Pappo AS; Vassal G; Crowley JJ; Bolejack V; Hogendoorn PC; Chugh R; Ladanyi M; Grippo JF; Dall G; Staddon AP; Chawla SP; Maki RG; Araujo DM; Geoerger B; Ganjoo K; Marina N; Blay JY; Schuetze SM; Chow WA; Helman LJ
    Cancer; 2014 Aug; 120(16):2448-56. PubMed ID: 24797726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.
    Kurmasheva RT; Dudkin L; Billups C; Debelenko LV; Morton CL; Houghton PJ
    Cancer Res; 2009 Oct; 69(19):7662-71. PubMed ID: 19789339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
    Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
    J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma.
    Ha HT; Griffith KA; Zalupski MM; Schuetze SM; Thomas DG; Lucas DR; Baker LH; Chugh R
    Am J Clin Oncol; 2013 Feb; 36(1):77-82. PubMed ID: 22237145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma.
    Wang YH; Han XD; Qiu Y; Xiong J; Yu Y; Wang B; Zhu ZZ; Qian BP; Chen YX; Wang SF; Shi HF; Sun X
    J Surg Oncol; 2012 Mar; 105(3):235-43. PubMed ID: 21866554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.
    Kolb EA; Kamara D; Zhang W; Lin J; Hingorani P; Baker L; Houghton P; Gorlick R
    Pediatr Blood Cancer; 2010 Jul; 55(1):67-75. PubMed ID: 20486173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
    Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
    Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
    Matsubara J; Yamada Y; Nakajima TE; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Oncology; 2008; 74(1-2):76-83. PubMed ID: 18544998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
    Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
    Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway.
    van Maldegem AM; Bovée JV; Peterse EF; Hogendoorn PC; Gelderblom H
    Eur J Cancer; 2016 Jan; 53():171-80. PubMed ID: 26765686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
    Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
    Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells.
    Bostedt KT; Schmid C; Ghirlanda-Keller C; Olie R; Winterhalter KH; Zapf J
    Exp Cell Res; 2001 Dec; 271(2):368-77. PubMed ID: 11716549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.